UK – Dexamethasone cut deaths by 35% in ventilated COVID-19 patients

Data from the UK’s RECOVERY trial show that dexamethasone significantly reduced deaths in patients hospitalised with COVID-19 and severe respiratory complications.

In the trial, a total of 2,104 patients were randomised to receive dexamethasone 6mg once per day for ten days and were compared with 4,321 patients randomised to usual care alone.

Among those who received usual care alone, 28-day mortality was highest in those who required ventilation (41%), intermediate in those patients who required oxygen only (25%), and lowest among those who did not require any respiratory intervention (13%)…